Iovance Biotherapeutics Missed Consensus Estimates
Thursday, May 8, 2025 at 4:01 PM ET
Iovance Biotherapeutics (IOVA) reported a loss of $0.36 per share on revenue of $49.32 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.25 per share on revenue of $80.50 million. The company missed consensus estimates by 44.00% while revenue grew 6,798.46% on a year-over-year basis.
Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer.
Earnings Whisper Grade
Power Rating
-
-
Reported Earnings
$-0.36
Earnings Whisper®
-
Consensus Estimate
$-0.25
Earnings Surprise
Earnings Growth
Reported Revenue
$49.32 Mil
Revenue Estimate
$80.50 Mil
Revenue Surprise
Revenue Growth